Endocannabinoids (eCBs) and neurotrophins, particularly brain-derived neurotrophic factor (BDNF), are potent neuromodulators found throughout the mammalian neocortex. Both eCBs and BDNF play critical roles in many behavioral and neurophysiological processes and are targets for the development of novel therapeutics. The effects of eCBs and BDNF are primarily mediated by the type 1 cannabinoid (CB1) receptor and the trkB tyrosine kinase receptor, respectively. Our laboratory and others have previously established that BDNF potentiates excitatory transmission by enhancing presynaptic glutamate release and modulating NMDA receptors. In contrast, we have shown that BDNF attenuates inhibitory transmission by inducing postsynaptic release of eCBs that act retrogradely to suppress GABA release in layer 2/3 of somatosensory cortex. Here, we hypothesized that BDNF also induces release of eCBs at excitatory synapses, which could have a mitigating or opposing effect on the direct presynaptic effects of BDNF. We found the highest levels of expression of CB1 and trkB and receptors in layers 2/3 and 5. Surprisingly, BDNF did not increase the frequency of spontaneous miniature excitatory postsynaptic currents (mEPSCs) onto layer 5 pyramidal neurons in somatosensory cortex, in contrast to its effects in the hippocampus and visual cortex. However, the effect of BDNF on mEPSC frequency in somatosensory cortex was unmasked by blocking CB1 receptors or disrupting eCB release. Thus, BDNF-trKB signaling regulates glutamate release in the somatosensory cortex via opposing effects, a direct presynaptic enhancement of release probability, and simultaneous postsynaptically-induced eCB release that decreases release probability via presynaptic CB1 receptors.
Interestingly, multiple reports have described evidence for cross-talk between neurotrophin and eCB signaling. Specifically, Zhong et al. (2015) showed that BDNF in midbrain dopamine neurons regulates eCB responses, cocaine-induced synaptic plasticity, and associative learning by selectively knocking down BDNF expression in dopaminergic neurons.
In the visual cortex, BDNF has been shown to oppose eCB-mediated forms of heterosynaptic long-term depression (LTD) at activated synapses by inducing homosynaptic long term potentiation (Huang, Yasuda, Sarihi, & Tsumoto, 2008) . Furthermore, there is evidence of BDNF and its involvement as a modulator of eCB-mediated synaptic plasticity in the hippocampus (Roloff, Anderson, Martemyanov, & Thayer, 2010) . Lastly, BDNF and eCB interactions have been demonstrated in mediating neuronal survival and protection against excitotoxicity (Khaspekov et al., 2004; Maison, Walker, Walsh, Williams, & Doherty, 2009 ).
BDNF may also be an important trigger for eCB synthesis and release. It is well established that eCB mobilization can be triggered by increases in intracellular calcium or activation of Gq coupled receptors and subsequent phospholipase C (PLC)-dependent increase in diacylglycerol (DAG), the precursor to 2-arachidonoylglycerol (2-AG) (Castillo, Younts, Chavez, & Hashimotodani, 2012; Hashimotodani, OhnoShosaku, & Kano, 2007) . In addition, we have recently shown that BNDF/trkB signaling also triggers PLC-dependent eCB release. BDNF, acting through postsynaptic trkB receptors, induces 2-AG release from pyramidal neurons at neocortical inhibitory synapses, which in turn suppresses GABA release from presynaptic terminals (Lemtiri-Chlieh & Levine, 2010; Zhao & Levine, 2014) . In fact, the suppressive effect of BDNF seems to be completely mediated by eCBs, because the effect of BDNF at these inhibitory synapses is completely prevented by blocking cannabinoid type 1 (CB1) receptors or interfering with eCB synthesis or release. Furthermore, we also showed that theta burst stimulationinduced release of endogenous BDNF can also trigger eCB synthesis and release resulting in inhibitory long-term depression (iLTD) (Zhao, Yeh, & Levine, 2015) .
In the present studies, we explored whether BDNF can also trigger the release of eCBs at excitatory synapses. It is known that BDNF can directly potentiate glutamatergic neurotransmission by enhancing presynaptic release probability (Carmignoto, Pizzorusso, Tia, & Vicini, 1997; Lessmann & Heumann, 1998; Li, Zhang, Lester, Schuman, & Davidson, 1998; Schinder et al., 2000; Tyler & Pozzo-Miller, 2001) , as well as enhancing postsynaptic NMDA receptor responsiveness (Crozier, Black, & Plummer, 1999; Levine, Crozier, Black, & Plummer, 1998; Lin et al., 1998; Madara & Levine, 2008) . Conversely, eCB signaling decreases release probability at synapses throughout the neocortex. However, it is not known if BDNF induces eCB release at excitatory synapses. We hypothesized that, if it occurs, BDNF-induced eCB release at excitatory synapses would act to mitigate the direct effects of BDNF.
| MATERIALS A ND METHODS

| Animal handling and slice preparation
All animal procedures were conducted using protocols approved by the University of Connecticut Institutional Animal Care and Use Committee. Postnatal Day 15-27 Swiss CD-1 (Charles River, Wilmington, MA) and C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) mice were anesthetized by 3.5% isoflurane inhalation, followed by decapitation.
Experiments were conducted on Swiss CD-1 mice except where noted.
Whole brains were removed and immersed in ice-cold slicing solution containing (in mM) 110 choline chloride, 2.5 KCl, 1.25 NaH 2 PO 4 -H 2 O, 25 NaHCO 3 , 0.5 CaCl 2 , 7 MgCl 2 -6H 2 O, 25 D-glucose, 11.6 sodium ascorbate, and 3.1 sodium pyruvate, equilibrated with 95% O 2 -5% CO 2 (pH 7.3, 310 6 5 mosmol/kg). Transverse slices (300 lm) containing somatosensory cortex were cut with a Dosaka EM DTK-1000 vibratome (Kyoto, Japan) and transferred to an incubating chamber. Slices were then incubated for 15 min at 33-35 8C in carboxygenated incubating solution containing (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 -H 2 O, 25 NaHCO 3 , 0.5 CaCl 2 , 3.5 MgCl 2 -6H 2 O, 25 D-glucose, 4 sodium lactate, 2 sodium pyruvate, and 0.4 ascorbic acid (pH 7.3, 310 6 5 mosmol/kg) before being transferred to room temperature. Slices were then individually transferred to a recording chamber (room temperature) fixed to the stage of an Olympus BX51WI upright microscope fitted with an 340 water-immersion objective lens (0.8 NA). The recording chamber was continuously perfused at 1.5-2.0 ml/min with carboxygenated artificial cerebrospinal fluid (aCSF) consisting of (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 -H 2 O, 25 NaHCO 3 , 2 CaCl 2 , 2 MgCl 2 -6H 2 O, and 25 D-glucose (pH 7.3, 305 6 5 mosmol/kg).
| Electrophysiology
Whole cell recordings were obtained from layer 5 somatosensory cortex pyramidal neurons. Neurons were visually identified by their morphology and position under infrared differential interference contrast video microscopy. Patch electrodes (2-4 MX) were pulled from borosilicate glass capillaries using a Flaming/Brown P-97 micropipette puller (Sutter Instrument, Novato, CA). Pipette internal solution contained (in mM) 4 KCl, 125 K-Gluconate, 10 HEPES, 10 Phosphocreatine, 1 EGTA, 0.20 CaCl 2 , 4 Na 2 -ATP, and 0.30 Na-GTP.
The sodium equilibrium potential (E Na ) with the use of the above internal and external solutions was close to 190 mV; thus EPSCs were recorded as inward currents. Cells were voltage clamped at 270 mV during recording. Miniature excitatory postsynaptic currents (mEPSCs) were isolated by bath perfusion of tetrodotoxin (TTX, 500 nM). All electrical currents were filtered at 2.9 kHz and digitized at >6 kHz using a HEKA EPC9 amplifier and ITC-16 digitizer (HEKA Elektronik, Darmstadt, Germany). Series resistance (R s ) was compensated up to 50% at 10-100 ls lag. Input resistance (R i ) was monitored with 10 mV (50 ms) hyperpolarizing voltage steps at the end of each sweep. Cells were rejected from analyses if R i changed by > 15% or fell below 50 MX during the course of an experiment.
| Chemicals
Unless otherwise stated, all drugs were obtained from Tocris Biosciences (Bristol, UK) and were delivered by bath perfusion. Drugs were first prepared as concentrated stock solution in solvents and stored at 220 8C. Stock solutions of WIN55-212,2, ANA-12, SR141716A, and AM404 were dissolved in 100% dimethyl sulfoxide (DMSO). The stock solution of BDNF was dissolved in 18 MX water. The stock solution of TTX was dissolved in aCSF. Drug stock solutions were diluted in aCSF on the day of recording to the final concentrations. The final concentration of DMSO did not exceed 0.1%, which by itself had no effect on synaptic transmission.
| Immunohistochemistry
Immunohistochemical staining of tissue sections from perfusion-fixed mice has been described previously (Yeh et al., 2014) . Briefly, animals were perfused transcardially with 4% paraformaldehyde/0.1 M sodium phosphate buffer (pH 7.4) after CO 2 asphyxiation. After transcardial perfusion, brains were removed and postfixed in 4% paraformaldehyde/ 0.1 M sodium phosphate buffer (pH 7.4) overnight at 4 8C. Coronal sections (15 lm) through the somatosensory cortex were cut using a cryostat (Bright Instruments, Bedfordshire, UK) and immunostained with the appropriate antibodies. Sections were immunostained using the following antibodies: guinea pig polyclonal CB1 (1:500, generously provided by Dr.
Ken Mackie, Indiana University), mouse monoclonal vGlut1 (1:500, Neuromab), rabbit polyclonal trkBH181 (1:100, Santa Cruz Biotechnology) and mouse monoclonal Map2 (1:1000, Sigma-Aldrich). Fluorescent secondary antibodies used were Jackson Immuno 488 donkey anti-guinea pig, Jackson Immuno Rhodamine donkey anti-mouse and Jackson Immuno Cy-5 donkey anti-rabbit. To confirm antibody specificity, we preincubated CB1 receptor and trkB receptor antibodies with their respective blocking peptides prior to overnight incubation on cryosectioned mouse brain tissue. In the case of both antibodies, the blocking peptides completely negated the fluorescent signals. We have previously shown that BDNF-trkB signaling triggers the release of eCBs at inhibitory synapses in layer 2/3 of mouse somatosensory cortex (Lemtiri-Chlieh & Levine, 2010; Zhao & Levine, 2014) , suggesting colocalization of CB1 and trkB receptors in this area. We have also shown that eCBs modulate excitatory synapses in layer 2/3 as well as layer 5 (Fortin & Levine, 2007) . To determine the pattern of co-localization of CB1 receptors and trkB receptors across cortical layers, we performed immunohistochemical labeling of coronal sections of mouse somatosensory cortex at P21-24. Antibodies for the vesicular glutamate transporter 1 (vGlut1) and microtubule associated protein 2 (Map2) were used as markers of presynaptic terminals and dendritic processes, respectively. CB1 and trkB receptors both exhibit their highest levels of expression in layers 2/3 and 5 in the somatosensory cortex (Figure 1a) , supporting functional interaction within these layers.
| Image and data analysis
We subsequently quantified this observation by measuring mean fluorescence intensity of CB1 receptor and trkB receptor protein expression within each cortical layer (Figure 1b) .
In an effort to visualize pre-and postsynaptic localization of the CB1 and trkB receptor at excitatory synapses in layer 5 via immunohistochemical analysis, we performed triple-labeling with antibodies against CB1, trkB, and the presynaptic glutamatergic marker, vGlut1 CB1 receptor expression was also observed around the soma of putative pyramidal neurons situated in layer 5 (Figure 1c) . We believe that these CB1 receptors are expressed in presynaptic inhibitory terminals, which contact the soma of pyramidal neurons, consistent with previous anatomical and physiological studies (Bodor et al., 2005; Egertova, Cravatt, & Elphick, 2003; Fortin & Levine, 2007; Katona, Sperlagh, et al., 1999; Katona, Urban, et al., 2006; Pertwee, 2008; Trettel, Fortin, & Levine, 2004; Trettel & Levine, 2002; Zhao & Levine, 2014; Zhao et al., 2015) . However, we cannot rule out the potential expression of CB1 receptors on the soma of pyramidal neurons as well.
| Effect of BDNF on spontaneous release probability at excitatory synapses
We first examined the effect of exogenous BDNF (20 ng/ml, 0.8 nM) on isolated AMPA-mediated mEPSCs in layer 5 of mouse somatosensory cortex. As illustrated by sample traces and group data in Figure   FIG block by ANA-12 were seen in both CD1 and C57 mice, thus data from the two strains were pooled for the above analysis.
| Endocannabinoid signaling opposes BDNF-mediated potentiation of excitatory neurotransmission
We hypothesized that the inability of BDNF to produce a net increase in mEPSC frequency in layer 5 somatosensory cortical neurons may be the result of BDNF-trkB induced release of eCBs that have an opposing effect on presynaptic release probability. We first confirmed the (Figure 3d ). Taken together, these data indicate that VGCCs contribute to spontaneous glutamatergic release at these synapses, and that cannabinoidmediated suppression of release requires VGCC activity, similar to what was reported for layer 2/3 inhibitory synapses (Madara & Levine, 2008; Trettel & Levine, 2002) .
To test whether BDNF-induced eCB release was mitigating the direct effect of BDNF, we examined the effect of BDNF (0.8 nM) in the presence of the CB1 receptor-specific inverse agonist, SR141716A (SR; 10 mM) (Figure 3) . In this experiment, SR was bath-applied for 10 minutes, followed by a 10 min perfusion of BDNF (0.8 nM) in the continued presence of SR. Representative traces from a single experiment are shown in Figure 3a . Application of SR resulted in a small but nonsignificant and transient increase in the frequency of mEPSCs in the majority of cells tested, as shown in the group data presented in Figure   3b . The amplitude of mEPSCs was not affected by SR alone (Figure 3c ).
As shown in the group data presented in Figure 3b , exogenous BDNF (0.8 nM) application in the presence of SR resulted in a statistically significant increase in mEPSC frequency. mEPSC frequency was increased to 159.4% 6 13.5% at 5 min of BDNF exposure in the presence of SR (ANOVA (F) 14,131 5 1.76, p < .05; SR 1.36 Hz 6 0.27; SR 1 BDNF 1.97
Hz 6 0.36; n 5 15, 5 animals) (Figure 3b ). These results support our hypothesis that BDNF/trkB signaling causes the release of eCBs at excitatory synapses, which directly opposes direct BDNF-mediated potentiation of glutamatergic release probability.
| BDNF triggers the release of eCBs from postsynaptic terminals in layer 5 of somatosensory cortex
Next, we employed the eCB transport inhibitor, AM404 (Beltramo et al., 1997; Di Marzo et al., 1994; Fegley et al., 2004; Hillard, Edgemond, Jarrahian, & Campbell, 1997) 4.20 Hz 6 1.63; p < .03; n 5 10, 2 animals). There was no effect of BDNF on mEPSC amplitude under these conditions (Figure 4b , bottom). In a set of parallel experiments, we added the DMSO vehicle (final concentration 0.1%) to the intracellular recording solution and found that it had no effect on the frequency or amplitude of mEPSCs (data not shown).
Taken together, these results suggest that BDNF induces eCB release at layer 5 excitatory synapses, and BDNF and eCB signaling have opposing direct effects on presynaptic release probability. BDNF by itself had no net effect at these synapses, but the direct effect of BDNF could be unmasked by either blocking CB1 receptor activation or inhibiting postsynaptic eCB release from pyramidal neurons.
| DISCUSSION
We recently showed that BDNF induces release of eCBs from postsynaptic pyramidal cells in layers 2/3 of somatosensory cortex (LemtiriChlieh & Levine, 2010) . This effect of BDNF is initiated by postsynaptic trkB signaling, requires downstream phospholipase-C ƴ (PLCƴ) signaling and is independent of metabotropic glutamate receptor (mGluR) activation (Zhao & Levine, 2014) . Furthermore, we established a role for endogenous BDNF in eCB-mediated plasticity at cortical inhibitory synapses, where strong theta burst stimulation (TBS) in layers 2/3 of somatosensory cortex can induce iLTD that requires BDNF-trkB and diacylglycerol (DAG) signaling . To complement these studies of BDNF and eCB interactions at cortical inhibitory synapses, we asked whether BDNF also triggers the release of eCBs at cortical excitatory synapses. We have shown that BDNF and eCBs exert opposing effects at cortical excitatory synapses (Fortin & Levine, 2007; Madara & Levine, 2008) . However, whether these two distinct signaling systems interact and the net functional outcome of these influences at excitatory synapses remains unexplored. We examined this issue in layer 5 of somatosensory cortex, since previous reports suggest that effects of eCBs on excitatory synapses are prominent in this region of the neocortex.
First, we employed immunohistochemistry on fixed, cryosectioned mouse somatosensory cortex with antibodies against the CB1 receptor and the trkB receptor. Our observations confirm previous studies exploring the synaptic localization of the CB1 (Egertova et al., 2003; Marsicano & Lutz, 1999; Matsuda, Bonner, & Lolait, 1993; Tsou, Brown, Sanudo-Pena, Mackie, & Walker, 1998) and trkB (Cabelli et al., 1996; Fryer et al., 1996; Miller & Pitts, 2000) receptors in the neocortex. Moreover, our immunohistochemical analysis provides an important first step in fully elucidating the synaptic topography of CB1 and trkB receptors at excitatory terminals. Scanning electron microscopy or super resolution microscopy may be required to obtain more precise visualization of receptor localization at the synapse. The use of high resolution microscopy may also aid in characterizing excitatory terminals with respect to receptor composition, that is, CB1 receptorpositive, trkB receptor-positive, or both.
We then examined the synaptic effects of eCB-CB1 receptor signaling and BDNF-trkB receptor signaling on spontaneous transmission at excitatory terminals within layer 5 of the somatosensory cortex. Surprisingly, we found that BDNF by itself did not increase mEPSC frequency (or amplitude) at these synapses. To confirm previous reports of BDNF effects on mEPSC frequency in other brain regions (Carmignoto et al., 1997; Li et al., 1998; Schinder, Berninger, & Poo, 2000; Tyler & Pozzo-Miller, 2001) , we examined the effect of BDNF in pyramidal neurons in the hippocampal CA1 region and layer 5 of visual cortex. We found that BDNF significantly increased mEPSC frequency in these regions, these effects were blocked by a trkB receptor antagonist, and these effects were consistent across two different mouse strains.
We next determined whether a BDNF-induced release of eCBs at excitatory synapses in layer 5 of somatosensory cortex might offset the direct presynaptic effects of BDNF. Blocking eCB signaling with a CB1 receptor antagonist unmasked a BDNF-induced increase in mEPSC frequency. Blocking postsynaptic release of eCBs had a similar effect. These results suggest that BDNF-trkB signaling induces the release of eCBs at excitatory synapses. While our group and others have previously described an increase in presynaptic release probability as a result of acute BDNF exposure in other brain regions, this is the first study examining synaptic effects of BDNF in layer 5 of mouse somatosensory cortex. In this region, we find that BDNF activates presynaptic trkB receptors to enhance spontaneous release probability, while simultaneously triggering the postsynaptic release of eCBs that act to decrease release via presynaptic CB1 receptors.
The presynaptic effects of BDNF on spontaneous glutamate transmission may have functional consequences of their own (Carmignoto et al., 1997; Lessmann & Heumann, 1998; Li et al., 1998; Schinder et al., 2000; Tyler & Pozzo-Miller, 2001 ) and may also translate to changes in evoked AP-dependent release. However, there is a lack of clear evidence for effects of BDNF on evoked glutamate release. This may in fact reflect the offsetting effect of BDNF-induced eCB release, and/or the effects of BDNF on evoked release may depend on specific AP activity patterns. It is also important to recognize that evoked (action potential-dependent) and spontaneous (action potential-independent) neurotransmitter release may utilize distinct vesicle pools that can be differentially regulated (Huntwork & Littleton, 2007; Littleton, Stern, Schulze, Perin, & Bellen, 1993; Maximov et al., 2007; Pang et al., 2011; Yoshihara et al., 1999) . Furthermore, nonoverlapping populations of postsynaptic NMDA receptors have been implicated in differentiating between spontaneous and evoked release (Atasoy et al., 2008; Melom, Akbergenova, Gavornik, & Littleton, 2013) .
In summary, our study contributes to uncovering region-specific roles of the eCB-CB1 receptor and BDNF-trkB receptor signaling pathways at cortical excitatory synapses. Moreover, we provide evidence that BDNF-trkB signaling may play an important role in triggering eCB release at cortical excitatory synapses. These two signaling systems have been implicated in various neurological disease states, including autism spectrum disorders, schizophrenia and epilepsy. There is, at present, a continuously growing body of evidence that the eCB system and BDNF system interact at various levels across multiple fields, including synaptic plasticity (De Chiara, Angelucci, et al., 2010; De Chiara, Motta, et al., 2013; Maison et al., 2009) , neuropathic pain (Luongo, Maione, & Di Marzo, 2014) , cortical development (Berghuis et al., 2005; Galve-Roperh et al., 2013) and neuroprotection in depression and epileptic seizures (Aguado et al., 2007; Aso et al., 2008; Khaspekov et al., 2004; Marsicano et al., 2003; Vinod et al., 2012) . Careful examination and elucidation of these interactions at excitatory and inhibitory synapses will be essential to the development and implementation of novel and effective therapeutic strategies. 
